GraniteShares彭博商品整体策略No K-1主动型ETF COMB 深 沪
已收盘 07-02 16:00:00 美东时间
24.058
+0.050
+0.21%
华盛通- 最 高24.13
- 今 开24.09
- 成交量 1.58万股
- 最 低 24.01
- 昨 收 24.0078
- 总市值 1.28亿
- 52周最高 28.05
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 18.6296
- 委 比 -60.00%
- 总股本 530.00万
- 历史最高 28.05
- 量 比 0.47
- 振 幅 0.50%
- 历史最低 2.5896
- 每 手 1
- 风险率 2.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V.
BRIEF-Kimball Electronics Acquires European-Based Medical CDMO, Helvoet Polymer Technologies B.V. July 1 (Reuters) - Kimball Electronics Inc KE.O : KIMBALL ELECTRONICS ACQUIRES EUROPEAN-BASED MEDICAL CDMO, HELVOET POLYMER TECHNOLOGIES B.V. KIMBALL ELECTRONICS - DEAL VALUED AT €90 MILLION ($103 MILLI
07-01 14:01
BRIEF-BT Group And Verizon To Combine International Operations In A 50:50 Joint Venture
BRIEF-BT Group And Verizon To Combine International Operations In A 50:50 Joint Venture June 29 (Reuters) - BT Group PLC BT.L : CO & VERIZON TO COMBINE THEIR RESPECTIVE INTERNATIONAL OPERATIONS IN A 50:50 JOINT VENTURE CO, VERIZON TO HOLD EQUAL VOTING RIGHTS VERIZON TO PAY BT EQUALISATION PAYMENT O
06-29 14:00
BRIEF-Elroy Air To Become Publicly Traded Company Via Business Combination With Inflection Point-Led Spac
BRIEF-Elroy Air To Become Publicly Traded Company Via Business Combination With Inflection Point-Led Spac June 26 (Reuters) - Columbus Circle Capital Corp II CMII.O : ELROY AIR TO BECOME PUBLICLY TRADED COMPANY VIA BUSINESS COMBINATION WITH INFLECTION POINT-LED SPAC ELROY AIR TO BECOME PUBLICLY TRAD
06-26 18:07
BRIEF-Segro Rejects Takeover Bid By Logistics Major Prologis
BRIEF-Segro Rejects Takeover Bid By Logistics Major Prologis June 24 (Reuters) - Prologis Inc PLD.N : STATEMENT RE POSSIBLE COMBINATION SEGRO BOARD UNEQUIVOCALLY REJECTS PROLOGIS COMBINATION PROPOSAL SEGRO SHAREHOLDERS TO RECEIVE 0.08 NEW PROLOGIS SHARES PER SEGRO SHARE COMBINATION IMPLIES VALUE OF
06-24 14:42
BRIEF-TSK Wins Three International Projects In Energy And Critical Raw Materials Sectors
BRIEF-TSK Wins Three International Projects In Energy And Critical Raw Materials Sectors June 19 (Reuters) - Tsk Electronica y Electricidad SA TSK.MC : SIGNS CONTRACT FOR 1 GW COMBINED CYCLE PLANT IN TEXAS WITH FERMI AMERICA SIGNS CONTRACT FOR DEVELOPMENT OF COMBINED-CYCLE POWER STATION WITH CAPACIT
06-19 15:34
BRIEF-Stellantis, Wayve, And Uber Collaborate To Deploy Robotaxis Globally
BRIEF-Stellantis, Wayve, And Uber Collaborate To Deploy Robotaxis Globally June 17 (Reuters) - Wayve: WAYVE: STELLANTIS, WAYVE, AND UBER COLLABORATING TO DEVELOP AND DEPLOY LEVEL 4 (DRIVERLESS) ROBOTAXIS GLOBALLY WAYVE: COLLABORATION COMBINES STELLANTIS' L4-READY PLATFORMS, WAYVE'S AI DRIVING TECHNO
06-17 16:00
BRIEF-OpenAI Plots Biggest ChatGPT Overhaul Since Launch - FT
BRIEF-OpenAI Plots Biggest ChatGPT Overhaul Since Launch - FT June 7 (Reuters) - OPENAI PLOTS BIGGEST CHATGPT OVERHAUL SINCE LAUNCH - FT OPENAI INTENDS TO TRANSFORM CHATGPT INTO A "SUPERAPP" THAT COMBINES CODING TOOLS AND AI AGENTS - FT Source text: https://tinyurl.com/pd3ut3mp Further company cover
06-07 12:04
BRIEF-Dexcom Says Use Of Dexcom G7 Leads To Improvement In Glucose Control In People With Type 2 Diabetes Not Using Insulin Versus Routine Care Control Group
BRIEF-Dexcom Says Use Of Dexcom G7 Leads To Improvement In Glucose Control In People With Type 2 Diabetes Not Using Insulin Versus Routine Care Control Group June 6 (Reuters) - Dexcom Inc DXCM.O : DEXCOM: USE OF DEXCOM G7 LEADS TO IMPROVEMENT IN GLUCOSE CONTROL IN PEOPLE WITH TYPE 2 DIABETES NOT USI
06-07 02:45
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses May 30 (Reuters) - Grail Inc GRAL.O : GRAIL REPORTS FULL RESULTS FROM NHS-GALLERI TRIAL DEMONSTRATING SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES AT 2026 ASCO ANNUAL MEETIN
05-30 20:14
BRIEF-Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl
BRIEF-Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl May 30 (Reuters) - Incyte Corp INCY.O : INCYTE - FRONTMIND TRIAL SHOWS 25% REDUCTION IN DISEASE PROGRESSION OR DEATH IN HIGH-RISK DLBCL INCYTE: PIVOTAL FRONTMIND TRIAL SHOWED TAFASITAMAB (MONJUVI
05-30 20:13
